Charles River Laboratories (NYSE:CRL) — Market Cap & Net Worth

$12.77 Billion USD  · Rank #1846

Market Cap & Net Worth: Charles River Laboratories (CRL)

Charles River Laboratories (NYSE:CRL) has a market capitalization of $12.77 Billion ($12.77 Billion) as of September 16, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #1846 globally and #701 in its home market, demonstrating a -5.41% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Charles River Laboratories's stock price $272.88 by its total outstanding shares 47738872 (47.74 Million). Also see how large is Charles River Laboratories's balance sheet for a full breakdown of the balance sheet.

Charles River Laboratories Market Cap History: 2015 to 2026

Charles River Laboratories's market capitalization history from 2015 to 2026. Data shows growth from $3.84 Billion to $13.03 Billion (13.69% CAGR). Also see Charles River Laboratories cash conversion from operations for how efficiently the company converts equity into cash flow.

Index Memberships

Charles River Laboratories is a constituent of 2 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
Dow Jones Biotechnology
DJUSBT
$1.16 Trillion 1.10% #12 of 39
S&P 500 Index
GSPC
$62.85 Trillion 0.01% #429 of 503

Weight: Charles River Laboratories's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Charles River Laboratories Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Charles River Laboratories's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Charles River Laboratories stock price today for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

2.37x

Charles River Laboratories's market cap is 2.37 times its annual revenue

Industry average: 0.63x Higher than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $3.64 Billion $1.68 Billion $154.76 Million 2.16x 23.50x
2017 $5.23 Billion $1.86 Billion $123.36 Million 2.81x 42.36x
2018 $5.40 Billion $2.27 Billion $226.37 Million 2.38x 23.87x
2019 $7.29 Billion $2.62 Billion $252.02 Million 2.78x 28.94x
2020 $11.93 Billion $2.92 Billion $364.30 Million 4.08x 32.74x
2021 $17.99 Billion $3.54 Billion $390.98 Million 5.08x 46.00x
2022 $10.40 Billion $3.98 Billion $486.23 Million 2.62x 21.39x
2023 $11.29 Billion $4.13 Billion $474.62 Million 2.73x 23.78x
2024 $8.81 Billion $4.05 Billion $10.30 Million 2.18x 855.84x
2025 $9.52 Billion $4.02 Billion -$144.34 Million 2.37x N/A

Competitor Companies of CRL by Market Capitalization

Companies near Charles River Laboratories in the global market cap rankings as of September 16, 2026. Review Charles River Laboratories (CRL) tangible net worth to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Charles River Laboratories by market ranking:

  • Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #88 globally with a market cap of $224.59 Billion USD.
  • Danaher Corporation (NYSE:DHR): Ranked #161 globally with a market cap of $147.88 Billion USD.
  • WuXi AppTec Co Ltd (SHG:603259): Ranked #476 globally with a market cap of $56.70 Billion USD ( CN¥387.49 Billion CNY).
  • Natera Inc (NASDAQ:NTRA): Ranked #578 globally with a market cap of $47.01 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#88 Thermo Fisher Scientific Inc NYSE:TMO $224.59 Billion $641.39
#161 Danaher Corporation NYSE:DHR $147.88 Billion $209.36
#476 WuXi AppTec Co Ltd SHG:603259 $56.70 Billion CN¥156.67
#578 Natera Inc NASDAQ:NTRA $47.01 Billion $350.78

Charles River Laboratories Historical Marketcap From 2015 to 2026

Between 2015 and today, Charles River Laboratories's market cap moved from $3.84 Billion to $ 13.03 Billion, with a yearly change of 13.69%.

Year Market Cap Change (%)
2026 $13.03 Billion +36.80%
2025 $9.52 Billion +8.06%
2024 $8.81 Billion -21.91%
2023 $11.29 Billion +8.49%
2022 $10.40 Billion -42.17%
2021 $17.99 Billion +50.80%
2020 $11.93 Billion +63.56%
2019 $7.29 Billion +34.97%
2018 $5.40 Billion +3.41%
2017 $5.23 Billion +43.65%
2016 $3.64 Billion -5.22%
2015 $3.84 Billion --

End of Day Market Cap According to Different Sources

On Sep 16th, 2026 the market cap of Charles River Laboratories was reported to be:

Source Market Cap
Yahoo Finance $12.77 Billion USD
MoneyControl $12.77 Billion USD
MarketWatch $12.77 Billion USD
marketcap.company $12.77 Billion USD
Reuters $12.77 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Charles River Laboratories

NYSE:CRL USA Diagnostics & Research
Market Cap
$13.03 Billion
Market Cap Rank
#1846 Global
#701 in USA
Share Price
$272.88
Change (1 day)
-0.08%
52-Week Range
$145.57 - $298.58
All Time High
$458.30
About

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more